Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours

Nature Communications

Volumn 6, Issue , 2015, Pages

  Litchfield, Kevin ^a   Summersgill, Brenda ^a   Yost, Shawn ^a   Sultana, Razvan ^a   Labreche, Karim ^a,b   Dudakia, Darshna ^a   Renwick, Anthony ^a   Seal, Sheila ^a   Al Saadi, Reem ^a   Broderick, Peter ^a   Turner, Nicholas C ^a   Houlston, Richard S ^a   Huddart, Robert ^a   Shipley, Janet ^a   Turnbull, Clare ^a,c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b SORBONNE UNIVERSITÉ   (France)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHASE PROMOTING COMPLEX SUBUNIT 3; CISPLATIN; MUCIN 12; MUCIN 5B; PROTEIN; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; XRCC2 PROTEIN; DNA BINDING PROTEIN; INTERLEUKIN DERIVATIVE; INTERLEUKIN-24; XRCC2 PROTEIN, HUMAN;

CANCER; CHROMOSOME; EMBRYONIC DEVELOPMENT; GENE EXPRESSION; MUTATION; TUMOR;

ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CHROMOSOMAL INSTABILITY; CHROMOSOME 12P; CHROMOSOME XQ; COPY NUMBER VARIATION; GENE MUTATION; GERM CELL TUMOR; HUMAN; HUMAN TISSUE; ISOCHROMOSOME; MAJOR CLINICAL STUDY; MALE; SEMINOMA; SOMATIC MUTATION; SPERMATOCYTE; ADULT; CHEMISTRY; CHROMOSOME 12; CHROMOSOME ABERRATION; COHORT ANALYSIS; CYTOLOGY; DISEASE COURSE; DNA MUTATIONAL ANALYSIS; EXOME; GENE DOSAGE; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; NEOPLASMS, GERM CELL AND EMBRYONAL; PROCEDURES; SINGLE NUCLEOTIDE POLYMORPHISM; TESTICULAR NEOPLASMS; TUMOR SUPPRESSOR GENE;

ADULT; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 12; CISPLATIN; COHORT STUDIES; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; EXOME; GENE DOSAGE; GENES, TUMOR SUPPRESSOR; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS, GERM CELL AND EMBRYONAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-KIT; SEMINOMA; SPERMATOCYTES; TESTICULAR NEOPLASMS;

EID: 84929256609     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6973     Document Type: Article

References (68)

1. Bray, F., Ferlay, J., Devesa, S. S., McGlynn, K. A. & Moller, H. Interpreting the1 international trends in testicular seminoma and nonseminoma incidence. Nat. Clin. Pract. Urol. 3, 532-543 (2006).
2. Ruf, C. G. et al. Changes in epidemiologic features of testicular germ cell cancer: age at diagnosis and relative frequency of seminoma are constantly and significantly increasing. Urol. Oncol. 32, 33.e31-33.e36 (2014).
3. de Haas, E. C. et al. Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann. Oncol. 24, 749-755 (2013).
4. Bujan, L. et al. Impact of chemotherapy and radiotherapy for testicular germ cell tumors on spermatogenesis and sperm DNA: a multicenter prospective study from the CECOS network. Fertil. Steril. 100, 673-680 (2013).
5. Rusner, C. et al. Risk of second primary cancers after testicular cancer in East and West Germany: a focus on contralateral testicular cancers. Asian J. Androl. 16, 285-289 (2014).
6. Nitzsche, B. et al. Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer. Br. J. Cancer 107, 1853-1863 (2012).
7. Sandberg, A. A., Meloni, A. M. & Suijkerbuijk, R. F. Reviews of chromosome studies in urological tumors.3. Cytogenetics and genes in testicular tumors. J. Urol. 155, 1531-1556 (1996).
8. Atkin, N. B. & Baker, M. C. Specific chromosome change, I(12p), in testicular-tumors. Lancet 2, 1349-1349 (1982).
9. Atkin, N. B. & Baker, M. C. I(12p) - specific chromosomal marker in seminoma and malignant teratoma of the testis. Cancer. Genet. Cytogenet. 10, 199-204 (1983).
10. Henegariu, O., Vance, G. H., Heiber, D., Pera, M. & Heerema, N. A. Triple-color FISH analysis of 12p amplification in testicular germ-cell tumors using 12p band-specific painting probes. J. Mol. Med. 76, 648-655 (1998).
11. Roelofs, H. et al. Restricted 12p amplification and RAS mutation in human germ cell tumors of the adult testis. Am. J. Pathol. 157, 1155-1166 (2000).
12. Summersgill, B. et al. Molecular cytogenetic analysis of adult testicular germ cell tumours and identification of regions of consensus copy number change. Br. J. Cancer 77, 305-313 (1998).
13. Zafarana, G. et al. 12p-amplicon structure analysis in testicular germ cell tumors of adolescents and adults by array CGH. Oncogene 22, 7695-7701 (2003).
14. Rodriguez, S. et al. Expression profile of genes from 12p in testicular germ cell tumors of adolescents and adults associated with i(12p) and amplification at 12p11.2-p12.1. Oncogene 22, 1880-1891 (2003).
15. McIntyre, A. et al. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res. 65, 8085-8089 (2005).
16. Kemmer, K. et al. KIT mutations are common in testicular seminomas. Am. J. Pathol. 164, 305-313 (2004).
17. Bignell, G. et al. Sequence analysis of the protein kinase gene family in human testicular germ-cell tumors of adolescents and adults. Genes Chromosomes Cancer 45, 42-46 (2006).
18. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
19. Kristensen, D. M. et al. Origin of pluripotent germ cell tumours: the role of microenvironment during embryonic development. Mol. Cell Endocrinol. 288, 111-118 (2008).
20. Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158 (2007).
21. Costello, M. et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res. 41, e67 (2013).
22. Nakai, Y. et al. KIT (c-kit oncogene product) pathway is constitutively activated in human testicular germ cell tumors. Biochem. Biophys. Res. Commun. 337, 289-296 (2005).
23. Ye, D. W. et al. P53 gene-mutations in chinese human testicular seminoma. J. Urol. 150, 884-886 (1993).
24. Heidenreich, A. et al. Immunohistochemical and mutational analysis of the p53 tumour suppressor gene aml the bcl-2 oncogene in primary testicular germ cell, tumours. APMIS 106, 90-99 (1998).
25. Laumann, R., Jucker, M. & Tesch, H. Point mutations in the conserved regions of the P53 tumor suppressor gene do not account for the transforming process in the jurkat acute lymphoblastic-leukemia T-cells. Leukemia 6, 227-228 (1992).
26. Zhang, J. F., Wan, L. X., Dai, X. P., Sun, Y. & Wei, W. Y. Functional characterization of Anaphase Promoting Complex/Cyclosome (APC/C) E3 ubiquitin ligases in tumorigenesis. Biochim. Biophys. Acta 1845, 277-293 (2014).
27. Kato, T. et al. Overexpression of CDC20 predicts poor prognosis in primary non-small cell lung cancer patients. J. Surg. Oncol. 106, 423-430 (2012).
28. Chang, D. Z. et al. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. J. Hematol. Oncol. 5, 15 (2012).
29. Marucci, G. et al. Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20. Virchows Arch. 453, 599-609 (2008).
30. Pawar, S. A. et al. C/EBP delta targets cyclin D1 for proteasome-mediated degradation via induction of CDC27/APC3 expression. Proc. Natl Acad. Sci. USA 107, 9210-9215 (2010).
31. Yu, C. et al. Discovery of biclonal origin and a novel oncogene SLC12A5 in colon cancer by single-cell sequencing. Cell Res. 24, 701-712 (2014).
32. Gonzalez-Perez, A. & Lopez-Bigas, N. Functional impact bias reveals cancer drivers. Nucleic Acids Res. 40, e169 (2012).
33. Gonzalez-Perez, A. et al. IntOGen-mutations identifies cancer drivers across tumor types. Nat. Methods 10, 1081-1082 (2013).
34. Sathirapongsasuti, J. F. et al. Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics 27, 2648-2654 (2011).
35. Gilbert, D. C. et al. Minimum regions of genomic imbalance in stage I testicular embryonal carcinoma and association of 22q loss with relapse. Genes Chromosomes Cancer 50, 186-195 (2011).
36. Summersgill, B., Osin, P. S., Lu, Y. J., Huddart, R. & Shipley, J. Chromosomal imbalances associated with carcinoma in situ and associated testicular germ cell tumours of adolescents and adults. Br. J. Cancer 85, 213-219 (2001).
37. Chao, H. H., He, X., Parker, J. S., Zhao, W. & Perou, C. M. Micro-scale genomic DNA copy number aberrations as another means of mutagenesis in breast cancer. PLoS ONE 7, e51719 (2012).
38. LeBron, C. et al. Genome-wide analysis of genetic alterations in testicular primary seminoma using high resolution single nucleotide polymorphism arrays. Genomics 97, 341-349 (2011).
39. Brown, P. R., Miki, K., Harper, D. B. & Eddy, E. M. A-kinase anchoring protein 4 binding proteins in the fibrous sheath of the sperm flagellum. Biol. Reprod. 68, 2241-2248 (2003).
40. Miki, K. et al. Targeted disruption of the Akap4 gene causes defects in sperm flagellum and motility. Dev. Biol. 248, 331-342 (2002).
41. Coy, J. F., Dressler, D., Wilde, J. & Schubert, P. Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer. Clin. Lab. 51, 257-273 (2005).
42. Schwaab, J. et al. Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. BMC Cancer 11, 363 (2011).
43. Danoy, P., Sonoda, E., Lathrop, M., Takeda, S. & Matsuda, F. A naturally occurring genetic variant of human XRCC2 (R188H) confers increased resistance to cisplatin-induced DNA damage. Biochem. Biophys. Res. Commun. 352, 763-768 (2007).
44. Lin, W. Y. et al. A role for XRCC2 gene polymorphisms in breast cancer risk and survival. J. Med. Genet. 48, 477-484 (2011).
45. Ng, P. C. & Henikoff, S. Predicting deleterious amino acid substitutions. Genome Res. 11, 863-874 (2001).
46. Sunyaev, S. et al. Prediction of deleterious human alleles. Hum. Mol. Genet. 10, 591-597 (2001).
47. Poddar, A., Stukenberg, P. T. & Burke, D. J. Two complexes of spindle checkpoint proteins containing Cdc20 and Mad2 assemble during mitosis independently of the kinetochore in Saccharomyces cerevisiae. Eukaryot. Cell 4, 867-878 (2005).
48. Monda, G., Ohashi, A., Yang, L., Rowley, M. & Couch, F. J. Tex14, a Plk1-regulated protein, is required for kinetochore-microtubule attachment and regulation of the spindle assembly checkpoint. Mol. Cell 45, 680-695 (2012).
49. Ruark, E. et al. Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14. Nat. Genet. 45, 686-689 (2013).
50. Chung, C. C. et al. Meta-analysis identifies four new loci associated with testicular germ cell tumor. Nat. Genet. 45, 680-685 (2013).
51. Rapley, E. A. et al. A genome-wide association study of testicular germ cell tumor. Nat. Genet. 41, 807-810 (2009).
52. Chemes, H. E., Brugo, S., Zanchetti, F., Carrere, C. & Lavieri, J. C. Dysplasia of the fibrous sheath: an ultrastructural defect of human spermatozoa associated with sperm immotility and primary sterility. Fertil. Steril. 48, 664-669 (1987).
53. Hotaling, J. M. & Walsh, T. J. Male infertility: a risk factor for testicular cancer. Nat. Rev. Urol. 6, 550-556 (2009).
54. Nathanson, K. L. et al. The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am. J. Hum. Genet. 77, 1034-1043 (2005).
55. Kuroda-Kawaguchi, T. et al. The AZFc region of the Y chromosome features massive palindromes and uniform recurrent deletions in infertile men. Nat. Genet. 29, 279-286 (2001).
56. Hemminki, K. & Li, X. Familial risk in testicular cancer as a clue to a heritable and environmental aetiology. Br. J. Cancer 90, 1765-1770 (2004).
57. Hasle, H., Mellemgaard, A., Nielsen, J. & Hansen, J. Cancer incidence in men with Klinefelter syndrome. Br. J. Cancer 71, 416-420 (1995).
58. Turnbull, C. et al. Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. Nat. Genet. 42, 604-607 (2010).
59. Gori, S. et al. Germ cell tumours of the testis. Crit. Rev. Oncol. Hematol. 53, 141-164 (2005).
60. Mai, P. L. et al. The international testicular cancer linkage consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urol. Oncol. 28, 492-499 (2010).
61. Forman, D. et al. Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA class 1 sib-pair analysis. Br. J. Cancer 65, 255-262 (1992).
62. Usanova, S. et al. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol. Cancer 9, 248 (2010).
63. Cavallo, F. et al. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to cisplatin and poly (ADP-ribose) polymerase inhibition. PLoS ONE 7, e51563 (2012).
64. Huddart, R. A., Wooster, R., Horwich, A. & Cooper, C. S. Microsatellite instability in human testicular germ cell tumours. Br. J. Cancer 72, 642-645 (1995).
65. Orkin, S. Molecular-cloning - a laboratory manual, 2nd edn (Sambrook, J., Fritsch, E.F., Maniatis, T.) Nature 343, 604-605 (1990).
66. Lahiri, D. K. & Nurnberger, J. I. A Rapid Nonenzymatic Method for the Preparation of Hmw DNA from Blood for Rflp Studies. Nucleic Acids Res. 19, 5444 (1991).
67. Gonzalez-Perez, A. et al. IntOGen-mutations identifies cancer drivers across tumor types. Nat. Methods 10, 1081-1082 (2013).
68. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).